All News

RheumNow Podcast square

Managing JDM with Calcinosis

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow and discusses a case of refractory juvenile dermatomyositis with calcinosis.

Read Article
gout.MTP1_.jpg

Black Adults Have a Higher Gout Risk

Jack Cush, MD

In a cross-sectional study of US adults, gout was more prevalent in black adults compared to white adults; possibly explained by sex-specific dietary differences and social determinants of health and clinical factors. 

Read Article
CV,risk,MI,heart,cardiac

Gout Flares Up Cardiac Risks

Jack Cush, MD

A large case-control study showed that gout patients who experienced a cardiovascular (CV) event were more likely to have had a recent (< 120 days) gout flare compared to those without CV events.

Read Article
RheumNow Podcast square

Social Media Questions (7.29.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and rheumatologist cases from the past week on RheumNow.com. This podcast is brought to you by StillsNow.com - be sure to sign up for our monthly StillsNow email and Monthly StillsNow Podcast.

Read Article
RheumNow Podcast square

Fever Pitch (7.15.2022)

Jack Cush, MD

Dr. Jack Cush reviews the new studies and drug approvals and new insights into febrile disorders from the past week on RheumNow.com

Read Article
FDA.approved.jpg

MTX + Pegloticase Combo FDA Approved

Jack Cush, MD

Horizon has announced that the U.S. Food and Drug Administration (FDA) has approved the expanded labeling of pegloticase (Krystexxa) injection to be co-administered with methotrexate (MTX), to improve response rates in patients with uncontrolled gout.

Read Article
renal.stone_.LBP_.jpg

ICYMI: Allopurinol Safety in CKD Patients

Jack Cush, MD

A study in the Annals of Internal Medicine reports chronic kidney disease (CKD) patients can be safely treated with allopurinol without an increased risk of mortality.

Read Article
Eval of 161 acute mono/oligoarthritis pts (gout, CPPD, controls) shows US of 2 joints (target jt, knee, MTP1, wrist) showed Dx accuracy (>90%), high specificity for gout (0.92-0.96) & CPPD (0.90-0.97); w/ sensitivity ranged from 0.73 to 0.85 for gout https://t.co/hW3pmz86kH https://t.co/IFVpINgybY

Links:

Dr. John Cush RheumNow ( View Tweet)
Gout T2T: Rheumatology societies target urate <5 mg/dl (0.30 mmol/l) or <6 mg/dl (<0.36 mmol/l) - below point of urate saturation -->MSU crystal dissolution. Achieving target reduces flares & tophi; but these clinical benefits take time. https://t.co/bR0vh01mvP https://t.co/JFJ1EWAhoF

Links:

Dr. John Cush RheumNow ( View Tweet)
MSK US in Gout? 71 gout pts on ULT followed x 1yr, 42% had at least one flare (median=2). Baseline US showing MSU deposits & inflammation significantly assoc w/ with # Flares (MSU score RR 1.17; power Doppler score RR 1.29) https://t.co/6IQo4JWtK0 https://t.co/Slm0fOvbnt

Links:

Dr. John Cush RheumNow ( View Tweet)
Gout T2T: Rheumatology societies target urate <5 mg/dl (0.30 mmol/l) or <6 mg/dl (<0.36 mmol/l) - below point of urate saturation -->MSU crystal dissolution. Achieving target reduces flares & tophi; but these clinical benefits take time. https://t.co/qfFSpGCJZp https://t.co/ILMAX3jj50

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums! Do you have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/cvmbzknQqA https://t.co/6mX5eRUNuU

Links:

Dr. John Cush RheumNow ( View Tweet)
Are you a fan of the RheumNow podcast? Please rate, like and review us wherever you get your podcast. We'd appreciate it!

Dr. John Cush RheumNow ( View Tweet)

Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study https://t.co/1fiNgBQUbr looks like lower ab response and drops over 6 mths - boosters important in our patients

Links:

Peter Nash drpnash ( View Tweet)

Gout Flares Up Cardiac Risks A large case-control study showed that gout patients who experienced a cardiovascular (CV) event were more likely to have had a recent (< 120 days) gout flare compared to those without CV events. https://t.co/HVmHZ0Pi7I https://t.co/XhdLTed5mr

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of cardiovascular effects of Colchicine: 21 RCTs (15,569 pts shows colchicine was superior to placebo reducing CV events; with lower risk recurrent pericarditis (RR 0.50), MACE (RR 0.67), & AFib recurrence (RR 0.68) https://t.co/oQEF7dmkH8 https://t.co/P7IKeZpcUB

Links:

Dr. John Cush RheumNow ( View Tweet)
Have you checked out our new sister-site, Still's Now? A new site for Still's disease, autoinflammatory & febrile disorders. https://t.co/oWEugnOB6k https://t.co/5jwiP2Xqrz

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums: Got a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/QUTIbK3r89 https://t.co/FZcTLREida

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatologist Survey: What do you rely on MOST in diagnosing Still’s disease? Sxs? Labs? Both? Criteria? Fever? Vote here: https://t.co/oANKpKqJA5 https://t.co/LIjRSBHNBi

Links:

Dr. John Cush RheumNow ( View Tweet)
MTX + Pegloticase Combo FDA Approved Horizon has announced that the FDA has approved the expanded labeling of pegloticase (Krystexxa) injection to be co-administered with methotrexate (MTX), to improve response rates in patients with uncontrolled gout. https://t.co/D71dmMuB9B https://t.co/jonfLqQ0lj

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×